Docetaxel and 5-FU continuous infusion (DF) versus epirubicin, cisplatin and 5-FU (ECF) for advanced gastric adenocarcinoma; a randomized phase II study

P. Thuss-Patience, Peter Reichardt(Helios Hospital Berlin-Buch), R. Junkers, Dirk Hennesser(Klinikum St. Georg), S. Micheel(Klinikum St. Georg), Bernd Dörken(Charité - Universitätsmedizin Berlin), Albrecht Kretzschmar(Roche (Switzerland)), M. Repp, Nikolaus Tiling(Charité - Universitätsmedizin Berlin), A. Vielhaber

European Journal of Cancer

April 1, 2001

10.1016/s0959-8049(01)81655-5

Cited by 2

Related Papers

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.6k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

|Journal of Clinical Investigation|1997|765

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|751

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

|European Journal of Cancer|2019|724